Eurocor Tech is proud to announce that the positive 5-year results¹ of the Freeway long-term study² have now been officially published in CVIR – the official journal of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
This recognition is a significant milestone for our product and underlines its efficacy and safety in providing optimal patient care, even over a 5-year period.
To those who might have missed the respective presentations at CIRSE and LINC congress: at the 5-year mark, the rate of freedom from clinically driven target lesion revascularization was statistically significantly better with 85.3% in the FREEWAY™ DEB group compared to 72.7% in the control group; p=0.032.
At the same time, the data demonstrated the high safety of FREEWAY™ as the study showcased no difference in late mortality compared to standard PTA treatment (Freedom from all-cause death FREEWAY™ 88.3 % vs. 87.3% standard PTA).
The study flyer can be accessed here.
The full scientific paper can be accessed here.
